Guselkumab is currently approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of interleukin -23 and inhibits its interaction with the IL-23 receptor.
IL-23 is an important driver in the pathogenesis of inflammatory diseases such as PsA, psoriasis and others.
PsA is a chronic, immune-mediated, inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis.
There is no known cure, and it is estimated that up to a third of the 14 m people who are living with psoriasis in Europe will also go on to develop PsA.
The CHMP positive opinion is based on data from DISCOVER-1 and DISCOVER-2, two first-in-class Phase 3 clinical studies, that demonstrated the efficacy and safety of guselkumab 100 mg q4w and q8w for the treatment of active PsA in adult patients. Data from these studies were recently published in The Lancet in March 2020.
DISCOVER-1 evaluated 381 participants with active PsA who had an inadequate response to standard therapies, including participants previously treated with anti-tumour necrosis factor alpha biologics.6 DISCOVER-2 included 739 patients who were biologic-naïve only and had an inadequate response to standard therapies.
Results published in The Lancet showed that in both studies, at week 24, the primary endpoints of American College of Rheumatology 20 % improvement (ACR20) achieved statistical significance (DISCOVER-1: p
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Hoth Therapeutics regains Nasdaq compliance
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
TME Pharma announces extension of financial visibility to May 2026